Microsatellite Instability Pathway and EMAST in Colorectal Cancer

Current Colorectal Cancer Reports

Volumn 13, Issue 1, 2017, Pages 73-80

  Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Colorectal cancer; Constitutional mismatch repair deficiency syndrome; Dinucleotide repeats; DNA microsatellites; DNA mismatch repair; DNA repair; EMAST (elevated microsatellite alterations at selected tetranucleotide repeats); Familial; Lynch syndrome; Lynch like syndrome; Microsatellite instability; MLH1 hypermethylation; Mononucleotide repeats; MSH3; Patient outcome; Patient survival; Sporadic; Tetranucleotide repeats; Trinucleotide repeats

Indexed keywords

DNA; FLUOROURACIL; MISMATCH REPAIR PROTEIN PMS2; MUTL PROTEIN HOMOLOG 1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL OUTCOME; COLORECTAL CANCER; DNA METHYLATION; DNA REPLICATION; DNA SEQUENCE; DNA STRUCTURE; ELEVATED MICROSATELLITE ALTERATIONS AT SELECTED TETRANUCLEOTIDE REPEAT; GENE MUTATION; GENETIC TRANSCRIPTION; GERMLINE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

EID: 85011579208     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-017-0352-y     Document Type: Review

References (60)

1. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–87.
2. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135:1079–99.
3. • Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149:1177–90. Recent review on pathways for sporadic colorectal cancer. Includes how biomarkers are formed during the pathways and how they might be used clinically for prognostic, diagnostic, and therapeutic approaches.
4. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.
5. Fearon ER, Carethers JM. Molecular subtyping of colorectal cancer—time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology. 2015;148:10–3.
6. • Carethers JM. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans Am Clin Climatol Assoc. 2016;127:81–97. Review on five human conditions with defective DNA mismatch repair.
7. • Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21:9253–61. Review of several mimics of Lynch syndrome and how to differentiate them based on genetic biomarkers.
8. Carethers JM. Differentiating Lynch-like from Lynch syndrome. Gastroenterology. 2014;146:602–4.
9. Carethers JM. DNA testing and molecular screening for colon cancer. Clin Gastroenterol Hepatol. 2014;12:377–81.
10. • Carethers JM, Koi M, Tseng-Rogenski S. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes. 2015;6:185–205. Only published review of EMAST and how it is generated and its implications as a biomarker.
11. Huang SC, Lee JK, Smith EJ, Doctolero R, Tajima A, Beck SE, et al. Evidence for an hMSH3 defect in familial hamartomatous polyps. Cancer. 2011;117:492–500.
12. Garcia M, Choi C, Kim HR, Daoud Y, Toiyama Y, Takahashi M, et al. Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology. 2012;143:48–50.
13. Tseng-Rogenski S, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS One. 2012;7(11):e50616.
14. Campregher C, Schmid G, Ferk F, Knasmüller S, Khare V, Kortüm B, et al. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PLoS One. 2012;7:e50541.
15. Haugen AC, Goel A, Yamada K, Marra G, Nguyen TP, Nagasaka T, et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res. 2008;68:8465–72.
16. Devaraj B, Lee A, Cabrera BL, et al. Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg. 2010;14:1521–8.
17. Lee S-Y, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang D-Y, et al. Elevated microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasia. Gastroenterology. 2010;139:1519–25.
18. Lee S-Y, Miyai K, Han HS, Hwang D-Y, Seong MK, Chung H, et al. Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. Dig Dis Sci. 2012;57:72–8.
19. Chang DK, Ricciardiello L, Goel A, Chang CL, Boland CR. Steady-state regulation of the human DNA mismatch repair system. J Biol Chem. 2000;275:29178.
20. • Stoffel EM, Boland CR. Genetics and genetic testing in hereditary colorectal cancer. Gastroenterology. 2015;149:1191–203. Updated review on common inherited syndromes that lead to colorectal cancer.
21. Kratz CP, Holter S, Etzler J, Lauten M, Pollett A, Niemeyer CM, et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet. 2009;46:418–20.
22. Jasperson KW, Samowitz WS, Burt RW. Constitutional mismatch repair-deficiency syndrome presenting as colonic adenomatous polyposis: clues from the skin. Clin Genet. 2011;80:394–7.
23. • Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, et al. Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet. 2016;99:337–51. Very first description of biallelic MSH3 mutations, with contributor parents having monoallelic MSH3 mutations, but no phenotype.
24. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808–11.
25. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870–5.
26. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998;95:8698–702.
27. Miyakura Y, Sugano K, Konishi F, Ichikawa A, Maekawa M, Shitoh K, et al. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology. 2001;121:1300–9.
28. Nakagawa H, Nuovo GJ, Zervos EE, Martin Jr EW, Salovaara R, Aaltonen LA, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. 2001;61:6991–5.
29. + T cell infiltration in colon cancer. PLoS One. 2014;9:e100461.
30. • Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014;146:643–646.e8. One of the first descriptions of double somatic hits to cause the genotype of microsatellite instability, but in the absence of Lynch syndrome and in absence of MLH1 hypermethylation.
31. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147:1308–16.
32. • Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, et al. Efficacy of 5-fluorouracil adjuvant therapy for patients with EMAST-positive stage II/III colorectal cancers. PLoS One. 2015;10:e0127591. Retrospective analysis of more than 200 patients characterized by EMAST status, showing 5-fluorouracil is still effective in EMAST-positive patients.
33. • Koi M, Garcia M, Choi C, Kim H-R, Koike J, Hemmi H, et al. Microsatellite alterations with allelic loss on 9p24.2 signify less aggressive colorectal cancer metastasis. Gastroenterology. 2016;150:944–55. First description of potential modulators of EMAST, identified from metachronous liver metastasis of EMAST-positive stage II/III colorectal cancer patients.
34. • Tseng-Rogenski S, Hamaya Y, Choi D, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology. 2015;148:579–89. Elegant finding of MSH3 mislocalization in the presence of IL-6 induced inflammation.
35. Carethers JM. One colon lumen but two organs. Gastroenterology. 2011;141:411–2.
36. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.
37. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148:88–99.
38. • Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148:77–87. Description of outcome of over 2000 patients based on genotyping colorectal cancer patients into 5 genetic categories.
39. Carethers JM. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Dig Dis Sci. 2015;60:711–21.
40. Jung B, Doctolero RT, Tajima A, Nguyen AK, Keku T, Sandler RS, et al. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology. 2004;126:654–9.
41. Jung BH, Beck SE, Cabral J, Chau E, Cabrera BL, Fiorino A, et al. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin. Gastroenterology. 2007;132:633–44.
42. Chung H, Young DJ, Lopez C, Le T-AT, Lee JK, Ream-Robinson D, et al. Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PLoS One. 2008;3:e3463.
43. Chung H, Lopez CG, Young DJ, Lai JF, Holmstrom J, Ream-Robinson D, et al. Flanking sequence specificity determines coding microsatellite heteroduplex and mutation rates with defective DNA mismatch repair. Oncogene. 2010;29:2172–80.
44. Chung H, Lopez CG, Holmstrom J, Young DJ, Lai JF, Ream-Robinson D, et al. Both microsatellite length and sequence context determine frameshift mutation rates in defective DNA mismatch repair. Hum Mol Genet. 2010;19:2638–4.
45. Chung H, Chaudhry J, Lai JF, Young DJ, Carethers JM. Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within activin receptor 2 (ACVR2). Mutat Res. 2012;729:73–80.
46. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;134:988–97.
47. • Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698–711. Comprehensive immunogenic analysis of colorectal cancers. Highlights acquirement of microsatellite unstable tumors for PD-1 expression.
48. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.
49. Ashktorab H, Ahuja S, Kannan L, Llor X, Ellis N, Xicola RM, et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget. 2016;7:34546–57.
50. van Oers JM, Edwards Y, Chahwan R, Zhang W, Smith C, Pechuan X, et al. The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair. Oncogene. 2014;33:3939–46.
51. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, et al. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014;4:592–605.
52. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117:123–31.
53. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.
54. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer. Gastroenterology. 2004;126:394–401.
55. Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, et al. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014;19:492–7.
56. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology. 2004;127:1678–84.
57. Suzuki S, Iwaizumi M, Tseng-Rogenski S, Hamaya Y, Miyajima H, Kanaoka S, et al. Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. Cancer Biol Ther. 2016;17:760–80.
58. Iwaizumi M, Tseng-Rogenski S, Carethers JM. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther. 2011;12:756–64.
59. Tajima A, Iwaizumi M, Tseng-Rogenski S, Cabrera BL, Carethers JM. Both hMutS and hMutS complexes participate in 5-fluorouracil cytotoxicity. PLoS One. 2011;6:e28117.
60. • Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. First-ever description of PD-1 blockade showing increased survival in patients with microsatellite unstable tumors.